EVALUATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER: SYSTEMATIC REVIEW AND TRIAL LEVEL META-ANALYSIS

被引：0
|
作者：
Adunlin, G. [1 ]
Dranitsaris, G. [2 ]
机构：
[1] Virginia Commonwealth Univ, Richmond, VA USA
[2] Augmentium Pharma Consulting Inc, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1536
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN203
引用
收藏
页码：A170 / A170
页数：1
相关论文
共 50 条
  • [41] Impact of LGR5 in colorectal cancer on overall and progression-free survival: a systematic review and meta-analysis
    Yang, Ling
    Lin, Yan
    Liu, Zhihui
    Li, Yongqiang
    Liu, Yuanfang
    Liang, Rong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (06): : 10537 - 10543
  • [42] EFFECTS OF METFORMIN USE ON PROGRESSION-FREE AND OVERALL SURVIVAL OF GLIOBLASTOMA CANCER PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Menon, S. S.
    Yadav, N.
    Yeddala, S. P.
    Doucette, J.
    Harris, C.
    Murimi-Worstell, I. B.
    VALUE IN HEALTH, 2021, 24 : S19 - S20
  • [43] PROGRESSION-FREE SURVIVAL IS A ROBUST SURROGATE ENDPOINT OF OVERALL SURVIVAL IN IMMUNOTHERAPY TRIALS OF HEPATOCELLULAR CARCINOMA
    Cabibbo, Giuseppe
    Celsa, Ciro
    Enea, Marco
    Battaglia, Salvatore
    Rizzo, Giacomo
    Busacca, Anita
    Matranga, Domenica
    Attanasio, Massimo
    Reig, Maria
    Craxi, Antonio
    Camma, Calogero
    HEPATOLOGY, 2020, 72 : 649A - 649A
  • [44] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos M.
    Sonneveld P.
    Manier S.
    Lam A.
    Roccia T.
    Schecter J.M.
    Cost P.
    Pacaud L.
    Poirier A.
    Tremblay G.
    Lan T.
    Valluri S.
    Kumar S.
    BMC Cancer, 24 (1)
  • [45] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Sonneveld, P.
    Nahi, H.
    Kumar, S.
    Hashim, M.
    Kulakova, M.
    Duran, M.
    Heeg, B.
    Lam, A.
    Dearden, L.
    VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
  • [46] Progression-free survival is a robust surrogate endpoint of overall survival in immunotherapy trials of hepatocellular carcinoma
    Celsa, C.
    Cabibbo, G.
    Enea, M.
    Battaglia, S.
    Rizzo, G. E. M.
    Busacca, A.
    Matranga, D.
    Attanasio, M.
    Reig, M.
    Craxi, A.
    Camma, C.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S35 - S35
  • [47] Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint
    Hurvitz, Sara A.
    CANCER TREATMENT REVIEWS, 2011, 37 (07) : 495 - 504
  • [48] Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer
    Hughes, Michael D.
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2008, 17 (05) : 487 - 495
  • [49] Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer
    Forsythe, Anna
    Chandiwana, David
    Barth, Janina
    Thabane, Marroon
    Baeck, Johan
    Tremblay, Gabriel
    BREAST CANCER-TARGETS AND THERAPY, 2018, 10 : 69 - 78
  • [50] The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis
    Dabush, Dor Reuven
    Shepshelovich, Daniel
    Shochat, Tzippy
    Tibau, Ariadna
    Amir, Eitan
    Goldvaser, Hadar
    CANCER TREATMENT REVIEWS, 2021, 100
12345